左氧氟沙星对从皮肤及软组织感染中分离出的一组特定厌氧菌的体外活性。
In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.
作者信息
Wexler H M, Molitoris E, Molitoris D, Finegold S M
机构信息
Veterans Administration Medical Center, Department of Medicine, UCLA School of Medicine, Los Angeles, California 90024, USA.
出版信息
Antimicrob Agents Chemother. 1998 Apr;42(4):984-6. doi: 10.1128/AAC.42.4.984.
Abstract
The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method. Ampicillin-sulbactam and cefoxitin inhibited 99% of the strains of this select group, levofloxacin and ofloxacin inhibited 73 and 50%, respectively, at 2 microg/ml, and ciprofloxacin inhibited 51% at 1 microg/ml. The geometric mean MIC of levofloxacin was lower than those of ofloxacin and ciprofloxacin for every group except Veillonella.
摘要
采用美国国家临床实验室标准委员会认可的沃兹沃思方法，将左氧氟沙星对从皮肤和软组织感染中分离出的一组特定厌氧菌（n = 175）的体外活性，与氧氟沙星、环丙沙星、氨苄西林 - 舒巴坦（2:1）、头孢西丁和甲硝唑的活性进行比较。氨苄西林 - 舒巴坦和头孢西丁抑制了该特定组中99%的菌株，左氧氟沙星和氧氟沙星在2微克/毫升时分别抑制了73%和50%的菌株，环丙沙星在1微克/毫升时抑制了51%的菌株。除韦荣球菌外，左氧氟沙星对每组的几何平均最低抑菌浓度均低于氧氟沙星和环丙沙星。
相似文献
1
In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.
Antimicrob Agents Chemother. 1998 Apr;42(4):984-6. doi: 10.1128/AAC.42.4.984.
2
Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.
Antimicrob Agents Chemother. 1999 Oct;43(10):2547-9. doi: 10.1128/AAC.43.10.2547.
3
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Antimicrob Agents Chemother. 1997 May;41(5):1193-5. doi: 10.1128/AAC.41.5.1193.
4
Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole.
Diagn Microbiol Infect Dis. 2000 Nov;38(3):181-3. doi: 10.1016/s0732-8893(00)00190-5.
5
The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
Int J Antimicrob Agents. 1999 Feb;11(2):139-43. doi: 10.1016/s0924-8579(98)00089-2.
6
An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
Ophthalmology. 2001 Oct;108(10):1826-9. doi: 10.1016/s0161-6420(01)00724-2.
7
Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
Antimicrob Agents Chemother. 1999 Jun;43(6):1475-9. doi: 10.1128/AAC.43.6.1475.
8
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Drugs. 1998 Sep;56(3):487-515. doi: 10.2165/00003495-199856030-00013.
9
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
Antimicrob Agents Chemother. 1997 Jul;41(7):1552-7. doi: 10.1128/AAC.41.7.1552.
10
In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
Antimicrob Agents Chemother. 2002 Mar;46(3):866-70. doi: 10.1128/AAC.46.3.866-870.2002.
引用本文的文献
1
Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model.
Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):395-402. doi: 10.1007/s13318-015-0271-8. Epub 2015 Mar 10.
2
Global fluoroquinolone resistance epidemiology and implictions for clinical use.
Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14.
3
Transposon mutagenesis of the anaerobic commensal, Bacteroides fragilis, using the EZ::TN5 transposome.
FEMS Microbiol Lett. 2012 Aug;333(2):94-100. doi: 10.1111/j.1574-6968.2012.02602.x. Epub 2012 Jun 18.
4
Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.
Infection. 2012 Jun;40(3):239-62. doi: 10.1007/s15010-012-0257-2. Epub 2012 Mar 30.
5
Bacteroides: the good, the bad, and the nitty-gritty.
Clin Microbiol Rev. 2007 Oct;20(4):593-621. doi: 10.1128/CMR.00008-07.
6
Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.
Clin Pharmacokinet. 2005;44(6):627-35. doi: 10.2165/00003088-200544060-00004.
7
Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Drugs. 2003;63(24):2769-802. doi: 10.2165/00003495-200363240-00008.
8
Levofloxacin: an updated review of its use in the treatment of bacterial infections.
Drugs. 2002;62(14):2127-67. doi: 10.2165/00003495-200262140-00013.
9
A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
本文引用的文献
1
Quinolone activity against anaerobes: microbiological aspects.
Drugs. 1995;49 Suppl 2:76-80. doi: 10.2165/00003495-199500492-00012.
2
Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
Drugs. 1995;49 Suppl 2:433-5. doi: 10.2165/00003495-199500492-00126.
3
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates.
Antimicrob Agents Chemother. 1995 May;39(5):1097-100. doi: 10.1128/AAC.39.5.1097.
4
The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
J Antimicrob Chemother. 1995 Jun;35(6):869-76. doi: 10.1093/jac/35.6.869.
5
Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use.
Clin Infect Dis. 1995 Jun;20 Suppl 2:S279-82. doi: 10.1093/clinids/20.supplement_2.s279.
6
Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
Drugs. 1994 Apr;47(4):677-700. doi: 10.2165/00003495-199447040-00008.
7
Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.
Antimicrob Agents Chemother. 1985 Apr;27(4):657-9. doi: 10.1128/AAC.27.4.657.
8
In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria.
J Antimicrob Chemother. 1986 Dec;18(6):693-701. doi: 10.1093/jac/18.6.693.
9
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
10
Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.
J Antimicrob Chemother. 1986 Jun;17(6):739-46. doi: 10.1093/jac/17.6.739.
Zotero 插件